
28 July 2021

Sensera Quarterly Update and Appendix 4C (*Revised)**

HIGHLIGHTS:

- **FQ4 revenue of US\$633k and cash receipts of US\$807k**
- **Abiomed FY22 demand confirmed at over US\$4M**
- **Cash position at US\$787k**

**Revised to include additional information per Listing Rule 4.7C at the end of this report.*

Sensera Limited (Company) (ASX:SE1) is providing Appendix 4C for the fourth quarter of the financial year 2021 (FY21). The Company achieved quarterly revenue of US\$633k up from US\$451k last quarter. There was also a material increase in cash receipts to US\$807k from US\$383k in FQ3.

The quarter ending cash position was US\$787k, as improved customer collections and cash generation from a warrant exercise drove cash flow in the quarter.

Abiomed, the company's largest volume customer, increased its sensor demand in the quarter. This is the start of a revenue ramp and demand is expected to continue to increase throughout FY22. Abiomed has indicated demand that is in excess of US\$4M for FY22 and has started placing orders to cover their near term requirements. The demand increase comes from the new sensor product production ramps that are now available as part of the industry leading Impella cardiac assist device.

NanoDiagnostics Incorporated ([NanoDX](#)) has continued to work towards production release of their SARS-CoV-2 detection system and until this work is complete it is not been in a position to seek FDA approval through the Emergency Use Authorization (EUA) process. As previously disclosed, whilst there is a risk that NanoDX may not satisfy the FDA's requirements for an EUA and/or the evaluation of NanoDX's EUA submission may take longer than expected, Sensera continue to work with NanoDX on the project.

The Company also engaged in two new sensor designs for customers in the quarter and has a robust pipeline of new opportunities that should help generate engineering based revenue and pre production builds during the coming quarters. This is a marked improvement in the new customer pipeline that had stalled as companies had been impacted by the pandemic for the past 18 months.

During FY20 and FY21 the Company received PPP of US\$1,242k in two separate loans of US\$621k each. The first loan forgiven was recognised as income 1H'21 and this was officially confirmed during the quarter. The Company is also expecting the second loan to be fully forgiven and should obtain confirmation late in Q1 FY22 or Q2. As the Company enters into FY22, it is expected that there will be overall operational improvement. Some of this is predicated on a 60% improvement in corporate costs on a year over year basis. Topline revenue growth is also expected to grow by over 30% to improve overall financial performance.

Management expects the business to continue to improve and believes that it has made meaningful progress in building out a MEMS based sensor business that will be sustainable by simplifying and focusing the business while reducing costs. In what has clearly been a difficult market environment during COVID-19, the Company has also moved multiple customers and opportunities forward to lay the foundation for FY22.

Additional information - Listing Rule 4.7C

Customer receipts increased by US\$424k to US\$807k due to increased revenue and improved collection performance and terms. Payments for operating activities for the quarter increased in line with revenue.

Overall cash (outflow) used in operating activities was US\$130k compared to US\$409k in the previous quarter.

Payments to related parties were US\$67k comprising director fees and emoluments excluding administrative and travel expense reimbursement.

This announcement was authorised for release by the Board of Directors

For more information, please contact:

Ralph Schmitt

Executive Director

+1 781 404 6500

info@sensera.com

Simon Peeke

Investor Relations

+61 404 443 323

speeke@sensera.com

About Sensera Limited (ASX: SE1):

Sensera Limited is an Internet of Things (IoT) sensor solution provider. The Company designs and manufactures MicroElectroMechanical Systems (MEMS) and sensors for applications that improve the way things are done.

Shares in Sensera Limited (ASX: SE1) are traded on the Australian Securities Exchange (ASX). For more information, please visit our website: www.sensera.com.

Any forward-looking statements in this announcement are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Sensera Limited

ABN

73 613 509 041

Quarter ended ("current quarter")

30 June 2021

Consolidated statement of cash flows	Current quarter \$U.S'000	Year to date (12 months) \$U.S'000
1. Cash flows from operating activities		
1.1 Receipts from customers	807	4,257
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(255)	(2,228)
(c) advertising and marketing	-	-
(d) leased assets	(142)	(295)
(e) staff costs	(264)	(1,891)
(f) administration and corporate costs	(227)	(2,039)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(49)	(711)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	621
1.8 Other (provide details if material)	-	
1.9 Net cash from / (used in) operating activities	(130)	(2,286)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(78)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$U.S'000	Year to date (12 months) \$U.S'000
2.2	Proceeds from disposal of:		
	(a) entities	-	7,444
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	466
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (transaction costs)	-	-
2.6	Net cash from / (used in) investing activities	-	7,832

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	395	395
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(5,745)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (finance lease repayments)	(308)	(819)
3.10	Net cash from / (used in) financing activities	87	(6,169)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	832	1,395
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(130)	(2,286)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	7,832

Consolidated statement of cash flows		Current quarter \$U.S'000	Year to date (12 months) \$U.S'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	87	(6,169)
4.5	Effect of movement in exchange rates on cash held	(2)	15
4.6	Cash and cash equivalents at end of period	787	787

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$U.S'000	Previous quarter \$U.S'000
5.1	Bank balances	787	832
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	787	832

6.	Payments to related parties of the entity and their associates	Current quarter \$U.S'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	67
6.2	Aggregate amount of payments to related parties and their associates included in item 2 and 3	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>The amount at 6.1 includes the payment of directors' fees and emoluments excluding reimbursement for administrative expenses and travel expenses.</p>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$U.S'000	Amount drawn at quarter end \$U.S'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$U.S'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(130)
8.2 Cash and cash equivalents at quarter end (item 4.6)	787
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	787
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	6.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: NA	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: NA.	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: NA	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:26 July 2021.....

Authorised by:By the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.